Pre-package a wide range of pharmaceutical products for the U.S. healthcare sector. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 4% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
This company is not turning a profit, so the market is pricing its sales instead: 0.3× for every dollar of annual revenue.
Fewer than three analyst price targets were published in the last 12 months, so none is shown.
The stock trades 57% below its peak. The market has cut its expectations for the company sharply.
There is $6.2M in the vault; even if every debt were paid off, $6.2M would remain.
A loss of $258K against $18.3M in annual sales. And on top of that, sales fell from the year before.
This stock swings about 1,696,040.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
The stock trades 57% below its five-year peak.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
The takeaway: PDRX’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.